Ignyta Inc. (RXDX)

26.95
0.03 0.09
Prev Close 26.98
Open 26.95
Day Low/High 26.95 / 27.00
52 Wk Low/High 5.70 / 27.10
Volume 4.23M
Avg Volume 2.57M
Exchange
Shares Outstanding 67.59M
Market Cap 1.82B
EPS -2.70
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Ignyta, Inc. To Roche Holding AG Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Ignyta, Inc. To Roche Holding AG Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ignyta, Inc.

Ignyta Reports FDA Clearance Of IND For RXDX-106, A Novel Immunomodulatory Agent And TYRO3, AXL, MER (TAM) Inhibitor

Ignyta Reports FDA Clearance Of IND For RXDX-106, A Novel Immunomodulatory Agent And TYRO3, AXL, MER (TAM) Inhibitor

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, today announced that the U.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Ignyta, Inc. To Roche Holding AG Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Ignyta, Inc. To Roche Holding AG Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ignyta, Inc.

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

Dow, S&P 500 and Nasdaq Finish Lower After Trump Signs Tax Bill Into Law

Dow, S&P 500 and Nasdaq Finish Lower After Trump Signs Tax Bill Into Law

Even with Friday's slump, the Dow, S&P 500 and Nasdaq finished higher for the week.

Stocks Trade Lower After Trump Signs Tax Bill Into Law

Stocks Trade Lower After Trump Signs Tax Bill Into Law

Stocks trade lower on Friday. Donald Trump signs the $1.5 trillion tax bill into law.

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

Stocks Trade Lower but Remain On Track for Weekly Gains

Stocks Trade Lower but Remain On Track for Weekly Gains

Stocks trade lower on Friday, in what is likely to be one of the final active trading days of the year as investors put the finishing touches on a record year for U.S. and global equities.

Roche And Ignyta Reach Definitive Merger Agreement

Roche And Ignyta Reach Definitive Merger Agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.

Ignyta To Participate At The Global Mizuho Investor Conference

Ignyta To Participate At The Global Mizuho Investor Conference

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, announced today that it will participate in investor meetings at the Global Mizuho Investor Conference on December 5,...

Ignyta To Present At The 29th Annual Piper Jaffray Healthcare Conference

Ignyta To Present At The 29th Annual Piper Jaffray Healthcare Conference

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.

Ignyta Reports Granting Of Inducement Awards

Ignyta Reports Granting Of Inducement Awards

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, announced today that it has issued two inducement awards to new non-executive employees.

Ignyta To Present At The Jefferies 2017 London Healthcare Conference

Ignyta To Present At The Jefferies 2017 London Healthcare Conference

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.

Ignyta Announces New Data Highlighting Immune Modulation Of RXDX-106 At The Society For Immunotherapy Of Cancer (SITC) Meeting

Ignyta Announces New Data Highlighting Immune Modulation Of RXDX-106 At The Society For Immunotherapy Of Cancer (SITC) Meeting

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, today announced new preclinical data for RXDX-106 - a novel immunomodulatory agent that demonstrated potent...

Ignyta Announces Third Quarter 2017 Company Highlights And Financial Results

Ignyta Announces Third Quarter 2017 Company Highlights And Financial Results

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the third quarter ended September 30, 2017.

Ignyta To Present At Credit Suisse 26th Annual Healthcare Conference

Ignyta To Present At Credit Suisse 26th Annual Healthcare Conference

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.

Ignyta Announces Pricing Of Public Offering Of Common Stock

Ignyta Announces Pricing Of Public Offering Of Common Stock

Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"), a biotechnology company focused on precision medicine in oncology, today announced the pricing of an underwritten public offering of 10.

Ignyta Announces Proposed Public Offering Of Common Stock

Ignyta Announces Proposed Public Offering Of Common Stock

Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"), a biotechnology company focused on precision medicine in oncology, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock.

Durability Of Entrectinib Treatment In ROS1+ NSCLC Patients (by BICR) (Graphic: Business Wire)

Durability Of Entrectinib Treatment In ROS1+ NSCLC Patients (by BICR) (Graphic: Business Wire)

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, today announced updated results from its clinical trials, including the STARTRK-2 trial, of entrectinib - an...

Ignyta Receives European Medicines Agency Prime Designation For Entrectinib In NTRK Fusion-Positive Solid Tumors

Ignyta Receives European Medicines Agency Prime Designation For Entrectinib In NTRK Fusion-Positive Solid Tumors

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation...

Ignyta Reports Granting Of Inducement Awards

Ignyta Reports Granting Of Inducement Awards

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, announced today that it has issued four inducement awards to new non-executive employees.

Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy Of RXDX-106 At 2017 AACR Tumor Immunology And Immunotherapy Meeting

Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy Of RXDX-106 At 2017 AACR Tumor Immunology And Immunotherapy Meeting

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, today announced new preclinical data for RXDX-106 - a novel immunomodulatory agent with potent anti-tumor...

Ignyta Announces Updated Data On Entrectinib In ROS1 NSCLC To Be Presented At The IASLC 18th World Conference On Lung Cancer

Ignyta Announces Updated Data On Entrectinib In ROS1 NSCLC To Be Presented At The IASLC 18th World Conference On Lung Cancer

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, today announced that updated data on entrectinib - an investigational, CNS-active, potent and selective...

First Week Of November 17th Options Trading For Ignyta (RXDX)

First Week Of November 17th Options Trading For Ignyta (RXDX)

Investors in Ignyta Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RXDX options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Ignyta To Present At Cantor Fitzgerald 2017 Global Healthcare Conference

Ignyta To Present At Cantor Fitzgerald 2017 Global Healthcare Conference

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.

Ignyta To Present At The Ladenburg Thalmann 2017 Healthcare Conference

Ignyta To Present At The Ladenburg Thalmann 2017 Healthcare Conference

Ignyta, Inc. (Nasdaq:RXDX),  a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.